<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614872</url>
  </required_header>
  <id_info>
    <org_study_id>CT2-LUNG-IV-IL-014</org_study_id>
    <nct_id>NCT02614872</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation</brief_title>
  <official_title>A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kamada, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kamada, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of intravenous GLASSIA® treatment in lung&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is clinical rationale to advocate the use of AAT(GLASSIA) therapy during episodes of&#xD;
      lung inflammation, including acute and chronic rejection. AAT may provide more specifically&#xD;
      targeted prevention of pathogenic inflammation, superior to that of general&#xD;
      immunosuppressants, with little risk. AAT is the main inhibitor of Neutrophil elastase(NE) in&#xD;
      the lower airways and patients with AAT deficiency have low concentrations of the protein in&#xD;
      this region of the lung. This explains the proteinase/antiproteinase theory of the&#xD;
      development of emphysema in deficient patients in which the amount of elastase released in&#xD;
      the lung exceeds the amount of AAT. The net result is persistence of elastase activity&#xD;
      leading to lung destruction and the pathological changes of emphysema. Administration of AAT&#xD;
      will help to prevent further destruction of the lung architecture and reduce the inflammatory&#xD;
      dysregulation that causes pulmonary dysfunction. It is expected that by attacking a specific&#xD;
      and previously untreated key component of the pathophysiological cycle of BOS, AAT therapy&#xD;
      would decrease the prevalence of BOS in lung transplant recipients and prolong life&#xD;
      expectancy of these patients. This will be an open label study in order to ensure safety, in&#xD;
      the frame of POC study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2016</start_date>
  <completion_date type="Actual">May 7, 2019</completion_date>
  <primary_completion_date type="Actual">April 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of subjects experiencing AEs and/or SAEs</measure>
    <time_frame>during the study</time_frame>
    <description>Incidence of subjects experiencing causally related AEs and/or SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and rate of Acute Rejection</measure>
    <time_frame>per year</time_frame>
    <description>Incidence and rate of Acute Rejection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual rate (per subject) of pulmonary infections</measure>
    <time_frame>per year</time_frame>
    <description>Annual rate (per subject) of pulmonary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of subjects who develop Bronchiolitis Obliterans</measure>
    <time_frame>during the study</time_frame>
    <description>Incidence of subjects who develop Bronchiolitis Obliterans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pulmonary Function Test</measure>
    <time_frame>Change from baseline and overall effect</time_frame>
    <description>Changes in Pulmonary Function Test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Transplantation, Lung Rejection</condition>
  <arm_group>
    <arm_group_label>GLASSIA®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Institution standard of care (SOC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLASSIA® and Institution standard of care (SOC)</intervention_name>
    <description>Alpha-1 Antitrypsin (AAT) [GLASSIA®] add-on pharmacotherapy and Institution standard of care (SOC)</description>
    <arm_group_label>GLASSIA®</arm_group_label>
    <other_name>GLASSIA and Institution standard of care (SOC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. Subject is planned to undergo first single or double lung transplant (including&#xD;
             heart-lung transplant) as per standard implantation procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has immunoglobulin A (IgA) deficiency and known anti IgA antibodies.&#xD;
&#xD;
          2. Known history of OR positive serological evidence at the time of screening for&#xD;
             hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), Parvovirus&#xD;
             B19 (PVB19) or human immunodeficiency virus (HIV) Type 1/2 infection&#xD;
&#xD;
          3. Subjects with a history of severe immediate hypersensitivity reactions, including&#xD;
             allergies, anaphylaxis to plasma products or any human proteins of different source.&#xD;
&#xD;
          4. Pregnant or lactating women at entry to study and women of child bearing potential,&#xD;
             who are unwilling to agree to continue to use acceptable methods of contraception&#xD;
             throughout the study.&#xD;
&#xD;
          5. Presence of psychiatric/ mental disorder or any other medical disorder which might&#xD;
             impair the subject's ability to give informed consent or to comply with the&#xD;
             requirements of the study protocol.&#xD;
&#xD;
          6. Alcohol abuse or history of alcohol abuse.&#xD;
&#xD;
          7. Illegal drugs.&#xD;
&#xD;
          8. Candidate for organ transplantation other than first lung or heart-lung&#xD;
             transplantation&#xD;
&#xD;
          9. Clinically significant bronchial stenosis unresponsive to dilation and/or stenting&#xD;
&#xD;
         10. Participation in another interventional clinical trial within 30 days prior to&#xD;
             baseline visit.&#xD;
&#xD;
         11. Inability to attend scheduled clinic visits and/or comply with the study protocol.&#xD;
&#xD;
         12. Any other factor that, in the opinion of the investigator, would prevent the subject&#xD;
             from complying with the requirements of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mordechai Kramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary institute, Rabin Medical Center, Israel.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Institute - Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 15, 2015</study_first_submitted>
  <study_first_submitted_qc>November 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

